We are analyzing https://link.springer.com/article/10.1007/s00262-012-1387-1.

Title:
Circulating tumor cells as therapy-related biomarkers in cancer patients | Cancer Immunology, Immunotherapy
Description:
Carcinomas (tumors of epithelial origin) are responsible for most of all new cancers in the industrialized countries. Due to the high mortality rate caused by the metastatic spread of aggressive cancer cells, there is an urgent demand in finding new biomarkers, which should detect early formation of metastases and monitor efficacy of systemic adjuvant therapy in a timely manner. It has been considered that the molecular analysis of cells which are shed from tumors into the blood system (circulating tumor cells (CTCs)) might provide new insights for the clinical management of cancer, probably far earlier than using traditional high-resolution imaging technologies. Clinical trials indicated that CTCs can be deployed for diagnostic, monitoring, and prognostic purposes. Furthermore, these cells are discussed to be suitable as predictive markers. In any case, identification of CTCs requires innovative and challenging technologies as detection methods should be specific, sensitive, standardized, and highly reproducible. Although many different approaches have been developed until now, only the CellSearch™ method has been cleared by the American Food and Drug Administration. Although the detection of CTCs has already shown to have a prognostic impact in many tumor entities including breast, prostate, lung and colon cancer, ongoing and future studies are aimed to explore whether CTCs can be used for an individual therapy decision making including novel immunotherapeutic approaches. This review discusses (1) different detection strategies for CTCs, (2) their clinical impact, and (3) the potential use of CTCs guiding the treatment of individual cancer patients.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Science
Education

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We're unsure how the site profits.

Some websites aren't about earning revenue; they're built to connect communities or raise awareness. There are numerous motivations behind creating websites. This might be one of them. Link.springer.com might be cashing in, but we can't detect the method they're using.

Keywords {🔍}

cancer, article, cells, google, scholar, pubmed, circulating, tumor, cas, patients, breast, pantel, clin, res, clinical, metastatic, oncol, detection, cell, blood, ctcs, tumour, terstappen, research, epithelial, prostate, med, riethdorf, doyle, access, cristofanilli, survival, privacy, cookies, content, analysis, search, immunotherapy, biomarkers, review, gorges, early, therapy, relevance, rev, brandt, miller, ann, transition, peripheral,

Topics {✒️}

month download article/chapter her2-positive breast cancer castration-resistant prostate cancer cancer stem/progenitor cells microvortex-generating herringbone-chip circulating lung-cancer cells article cancer immunology de bono js therapy-related biomarkers epithelial-mesenchymal transition markers epcam-based detection due circulating tumour cells focussed research reviews full article pdf cancer metastasis rev early breast cancer disseminating tumour cells circulating tumor cells circulating cancer cells emerging tumor biomarkers single cancer cells molecular biomarker analyses viable dtcs/ctcs privacy choices/manage cookies metastatic breast cancer related subjects primary breast cancer circulating tumor dna disseminated tumor cells aggressive cancer cells disseminating cancer cells epithelial tumor cells detect early formation circulating melanoma cells european economic area breast cancer display nonmetastatic breast cancer individual cancer patients article gorges gorges & klaus pantel systemic adjuvant therapy metastatic colorectal cancer advanced prostate cancer breast cancer patients precision oncology adjuvant chemotherapy cancer immunotherapy hypoxia promotes dissemination cell search system single cell profiling

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Circulating tumor cells as therapy-related biomarkers in cancer patients
         description:Carcinomas (tumors of epithelial origin) are responsible for most of all new cancers in the industrialized countries. Due to the high mortality rate caused by the metastatic spread of aggressive cancer cells, there is an urgent demand in finding new biomarkers, which should detect early formation of metastases and monitor efficacy of systemic adjuvant therapy in a timely manner. It has been considered that the molecular analysis of cells which are shed from tumors into the blood system (circulating tumor cells (CTCs)) might provide new insights for the clinical management of cancer, probably far earlier than using traditional high-resolution imaging technologies. Clinical trials indicated that CTCs can be deployed for diagnostic, monitoring, and prognostic purposes. Furthermore, these cells are discussed to be suitable as predictive markers. In any case, identification of CTCs requires innovative and challenging technologies as detection methods should be specific, sensitive, standardized, and highly reproducible. Although many different approaches have been developed until now, only the CellSearch™ method has been cleared by the American Food and Drug Administration. Although the detection of CTCs has already shown to have a prognostic impact in many tumor entities including breast, prostate, lung and colon cancer, ongoing and future studies are aimed to explore whether CTCs can be used for an individual therapy decision making including novel immunotherapeutic approaches. This review discusses (1) different detection strategies for CTCs, (2) their clinical impact, and (3) the potential use of CTCs guiding the treatment of individual cancer patients.
         datePublished:2013-01-12T00:00:00Z
         dateModified:2013-01-12T00:00:00Z
         pageStart:931
         pageEnd:939
         sameAs:https://doi.org/10.1007/s00262-012-1387-1
         keywords:
            Cancer
            EMT
            CTCs
            DTCs
            Metastasis
            Biomarker
            Oncology
            Immunology
            Cancer Research
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-012-1387-1/MediaObjects/262_2012_1387_Fig1_HTML.gif
         isPartOf:
            name:Cancer Immunology, Immunotherapy
            issn:
               1432-0851
               0340-7004
            volumeNumber:62
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Tobias M. Gorges
               affiliation:
                     name:University Medical Center Hamburg-Eppendorf
                     address:
                        name:Institute of Tumor Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Klaus Pantel
               affiliation:
                     name:University Medical Center Hamburg-Eppendorf
                     address:
                        name:Institute of Tumor Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Circulating tumor cells as therapy-related biomarkers in cancer patients
      description:Carcinomas (tumors of epithelial origin) are responsible for most of all new cancers in the industrialized countries. Due to the high mortality rate caused by the metastatic spread of aggressive cancer cells, there is an urgent demand in finding new biomarkers, which should detect early formation of metastases and monitor efficacy of systemic adjuvant therapy in a timely manner. It has been considered that the molecular analysis of cells which are shed from tumors into the blood system (circulating tumor cells (CTCs)) might provide new insights for the clinical management of cancer, probably far earlier than using traditional high-resolution imaging technologies. Clinical trials indicated that CTCs can be deployed for diagnostic, monitoring, and prognostic purposes. Furthermore, these cells are discussed to be suitable as predictive markers. In any case, identification of CTCs requires innovative and challenging technologies as detection methods should be specific, sensitive, standardized, and highly reproducible. Although many different approaches have been developed until now, only the CellSearch™ method has been cleared by the American Food and Drug Administration. Although the detection of CTCs has already shown to have a prognostic impact in many tumor entities including breast, prostate, lung and colon cancer, ongoing and future studies are aimed to explore whether CTCs can be used for an individual therapy decision making including novel immunotherapeutic approaches. This review discusses (1) different detection strategies for CTCs, (2) their clinical impact, and (3) the potential use of CTCs guiding the treatment of individual cancer patients.
      datePublished:2013-01-12T00:00:00Z
      dateModified:2013-01-12T00:00:00Z
      pageStart:931
      pageEnd:939
      sameAs:https://doi.org/10.1007/s00262-012-1387-1
      keywords:
         Cancer
         EMT
         CTCs
         DTCs
         Metastasis
         Biomarker
         Oncology
         Immunology
         Cancer Research
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-012-1387-1/MediaObjects/262_2012_1387_Fig1_HTML.gif
      isPartOf:
         name:Cancer Immunology, Immunotherapy
         issn:
            1432-0851
            0340-7004
         volumeNumber:62
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Tobias M. Gorges
            affiliation:
                  name:University Medical Center Hamburg-Eppendorf
                  address:
                     name:Institute of Tumor Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Klaus Pantel
            affiliation:
                  name:University Medical Center Hamburg-Eppendorf
                  address:
                     name:Institute of Tumor Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Cancer Immunology, Immunotherapy
      issn:
         1432-0851
         0340-7004
      volumeNumber:62
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University Medical Center Hamburg-Eppendorf
      address:
         name:Institute of Tumor Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
         type:PostalAddress
      name:University Medical Center Hamburg-Eppendorf
      address:
         name:Institute of Tumor Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Tobias M. Gorges
      affiliation:
            name:University Medical Center Hamburg-Eppendorf
            address:
               name:Institute of Tumor Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
               type:PostalAddress
            type:Organization
      name:Klaus Pantel
      affiliation:
            name:University Medical Center Hamburg-Eppendorf
            address:
               name:Institute of Tumor Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Institute of Tumor Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
      name:Institute of Tumor Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(191)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.98s.

LINK . SPRINGER . COM {}